Compare iShares MSCI Singapore ETF (EWS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.79, while Zimmer Biomet Holdings Inc trades at $93.62 (market cap $17.44B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while iShares MSCI Singapore ETF pays none, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| EWS | ZBH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $32.09 | $107.71 |
52-Week Low | $26.47 | $79.58 |
Market Cap | — | $17.44B |
Enterprise Value | — | $24.49B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS trades at $31.825, up 0.62% with strong technical momentum as moving averages signal bullish alignment. The ETF benefits from Singapore's economic resilience and AI-driven growth narrative, though key financial ratios remain undisclosed. Recent news highlights Singapore's strategic positioning in Asian markets and financial sector strength, with a dividend of $0.52 scheduled for June 2026.
Outlook remains positive given technical strength and regional economic tailwinds, but overbought RSI readings suggest near-term consolidation risk. The concentrated financials exposure (54% of holdings) ties performance to banking sector stability, while AI infrastructure investments offer growth catalysts. Investors should monitor Singapore's economic policies and global market volatility.
Zimmer Biomet (ZBH) trades at $92.94, up 2.1% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 70% gross margin and positive cash flow trends, though net income margin has declined from 13.8% in 2023 to 8.6% in 2025. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase, indicating management confidence.
ZBH presents a moderate growth opportunity with a consensus price target of $97.67, offering ~5% upside. Risks include rising debt levels and competitive pressures in medical devices. Analyst sentiment is mixed with 40% buy ratings, but institutional activity and strategic acquisitions support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
